Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Updated on: September 27,2024

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Updated on:September 27,2024

Some cervical cancer screening strategies more cost-effective

(HealthDay)—A cervical cancer screening strategy that involves cytologic testing every three years from ages 21 to 29 years and then continuing cytologic testing or switching to low-cost high-risk hum

Updated on: May 21,2024

Some cervical cancer screening strategies more cost-effective

(HealthDay)—A cervical cancer screening strategy that involves cytologic testing every three years from ages 21 to 29 years and then continuing cytologic testing or switching to low-cost high-risk hum

Updated on:May 21,2024

New study helps explain the anti-cancer properties of mannose sugar

bySanford Burnham Prebys Medical Discovery InstituteProposed model for the mechanism underlying anticancer activity of mannose in mannose phosphate isomerase knockout (MPI-KO) human cancer cells

Updated on: January 13,2024

New study helps explain the anti-cancer properties of mannose sugar

bySanford Burnham Prebys Medical Discovery InstituteProposed model for the mechanism underlying anticancer activity of mannose in mannose phosphate isomerase knockout (MPI-KO) human cancer cells

Updated on:January 13,2024

Researchers report results in rare gynecologic cancers from DART immunotherapy trial

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of pat

Updated on: February 03,2024

Researchers report results in rare gynecologic cancers from DART immunotherapy trial

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of pat

Updated on:February 03,2024

Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term an

Updated on: January 04,2024

Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

by NRG OncologyCredit: Unsplash/CC0 Public DomainResults from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term an

Updated on:January 04,2024

Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer

byUniversity of Texas M. D. Anderson Cancer CenterOncoprint of targeted somatic gene variants of tumors in patients with anaplastic thyroid cancer (atc) enrolled in cohorts 1 to 3. Credit:

Updated on: November 11,2024

Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer

byUniversity of Texas M. D. Anderson Cancer CenterOncoprint of targeted somatic gene variants of tumors in patients with anaplastic thyroid cancer (atc) enrolled in cohorts 1 to 3. Credit:

Updated on:November 11,2024

New research may hold key to better treatments for aggressive brain cancer

by Spectrum HealthPrakash Chinnaiyan, M.D., a physician scientist in the Department of Radiation Oncology at Corewell Health in Southeast, Mich. Credit: Elizabeth Debeliso, Corewell HealthFor decades,

Updated on: January 13,2024

New research may hold key to better treatments for aggressive brain cancer

by Spectrum HealthPrakash Chinnaiyan, M.D., a physician scientist in the Department of Radiation Oncology at Corewell Health in Southeast, Mich. Credit: Elizabeth Debeliso, Corewell HealthFor decades,

Updated on:January 13,2024

Novel urine-based test for non-invasive detection of bladder cancer

byUniversity of BirminghamCredit: designer 491A collaboration between University of Birmingham researchers and liquid biopsy cancer detection and screening company Nonacus, has resulted in a nov

Updated on: January 15,2024

Novel urine-based test for non-invasive detection of bladder cancer

byUniversity of BirminghamCredit: designer 491A collaboration between University of Birmingham researchers and liquid biopsy cancer detection and screening company Nonacus, has resulted in a nov

Updated on:January 15,2024

How colliding genetic processes drive aggressive cancers

byUniversity of Chicago Medical CenterLoss of CDK12 promotes large TD formation. Credit:Nature Cancer(2024). DOI: 10.1038/s43018-024-00848-4Cancer researchers at the University of Ch

Updated on: December 01,2024

How colliding genetic processes drive aggressive cancers

byUniversity of Chicago Medical CenterLoss of CDK12 promotes large TD formation. Credit:Nature Cancer(2024). DOI: 10.1038/s43018-024-00848-4Cancer researchers at the University of Ch

Updated on:December 01,2024

Researchers discover incredible HULLK that controls prostate cancer progression

by University of Virginia Health SystemDan Gioeli, Ph.D., of the University of Virginia School of Medicine, has identified a key to controlling the growth and progression of prostate cancer, the secon

Updated on: June 19,2024

Researchers discover incredible HULLK that controls prostate cancer progression

by University of Virginia Health SystemDan Gioeli, Ph.D., of the University of Virginia School of Medicine, has identified a key to controlling the growth and progression of prostate cancer, the secon

Updated on:June 19,2024

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030

Updated on: January 26,2024

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030

Updated on:January 26,2024

Study finds AI empowers patients before and after seeing physicians for radiation oncology treatment

by Northwestern UniversityCredit: Pixabay/CC0 Public DomainCancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers?A new

Updated on: April 06,2024

Study finds AI empowers patients before and after seeing physicians for radiation oncology treatment

by Northwestern UniversityCredit: Pixabay/CC0 Public DomainCancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers?A new

Updated on:April 06,2024